Developing concepts in negative symptoms: Primary vs secondary and apathy vs expressio

Journal of Clinical Psychiatry

Volumn 75, Issue SUPPL. 1, 2014, Pages 3-7

  Brian Kirkpatrick, B K ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BITOPERTIN; GALANTAMINE; PLACEBO;

ADVERSE OUTCOME; AFFECT; APATHY; ARTICLE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; EMOTIONALITY; FACIAL EXPRESSION; HUMAN; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SUBSTANCE ABUSE; ANHEDONIA; BEHAVIOR; CLASSIFICATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SCHIZOPHRENIA; STANDARD;

ANHEDONIA; APATHY; BEHAVIORAL SYMPTOMS; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84898678953     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13049su1c.01     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
2. Griesinger W. Mental Pathology and Therapeutics (1867). Robertson CL, Rutherford J, trans. New York, NY: Hafner Publishing Co; 1965.
3. Kraepelin E. Dementia Praecox and Paraphrenia (1919). Barclay RM, trans. Robertson GM, ed. Huntington, NY: Robert E. Krieger Publishing Co Inc; 1971.
4. Bobes J, Arango C, Garcia-Garcia M, et al. CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280-286. doi:10.408/JCP.08m04250yel PubMed
5. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788. doi:10.101/archpsyc.1982. 0429070205 PubMed
6. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261 PubMed
7. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219. doi:10.1093/schbul/sbj053 PubMed
8. Kring AM, Gur RE, Blanchard JJ, et al. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013;170(2):165-172. doi:10.176/api.ajp.2012.12010109 PubMed
9. Kirkpatrick B, Strauss GP, Nguyen L, et al. The Brief Negative Symptom Scale: psychometric properties. Schizophr Bull. 2011;37(2):300-305. doi:10.1093/schbul/sbq059 PubMed
10. Horan WP, Kring AM, Blanchard JJ. Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull. 2006;32(2):259-273. doi:10.1093/schbul/ sbj09 PubMed
11. Gard DE, Kring AM, Gard MG, et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93(1-3):253-260. doi:10.1016/j.schres.207.03.08 PubMed
12. Strauss GP, Wilbur RC, Warren KR, et al. Anticipatory vs consummatory pleasure: what is the nature of hedonic deficits in schizophrenia? Psychiatry Res. 2011;187(1-2):36-41. doi:10.1016/j.psychres.201.01.012 PubMed
13. Beck AT, Rector NA. Cognitive approaches to schizophrenia: theory and therapy. Annu Rev Clin Psychol. 2005;1(1):577-606. doi:10.146/anurev.clinpsy.1. 102803.14205 PubMed
14. Morrison AK. Cognitive behavior therapy for people with schizophrenia. Psychiatry (Edgmont). 2009;6(12):32-39. PubMed
15. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013-1022. doi:10.1093/schbul/sbl057 PubMed
16. Tandon R, Jibson M. Negative symptoms of schizophrenia: how to treat them most effectively. Curr Psychiatry. 2002;1(9):36-42.
17. Mulholland C, Cooper S. The symptom of depression in schizophrenia and its management. Adv Psychiatr Treat. 2000;6(3):169-177. doi:10.192/apt.6.3.169
18. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545-1573. doi:10.1517/1465656.201.626769 PubMed
19. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004:6(suppl 2);3-7. PubMed
20. Schmits E, Quertemont E. So called ?soft? drugs: cannabis and the amotivational syndrome. Rev Med Liege. 2013;68(5-6):281-286. PubMed
21. Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry. 2008;7(3):143-147. PubMed
22. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776-786. doi:10.101/archgenpsychiatry.2012.169 PubMed
23. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32(2):238-245. doi:10.1093/schbul/sbj013 PubMed
24. Strauss GP, Hong LE, Gold JM, et al. Factor structure of the Brief Negative Symptom Scale. Schizophr Res. 2012;142(1-3):96-98. doi:10.1016/j. schres.2012.09.07 PubMed
25. Kimhy D, Yale S, Goetz RR, et al. The factorial structure of the Schedule for the Deficit Syndrome in schizophrenia. Schizophr Bull. 2006;32(2):274-278. doi:10.1093/schbul/sbi064 PubMed
26. Nakaya M, Ohmori K. A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res. 2008;158(2):256-259. doi:10.1016/j.psychres.207.10.08 PubMed
27. Galderisi S, Bucci P, Mucci A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 2013;147(1):157-162. doi:10.1016/j. schres.2013.03.020 PubMed
28. Liemburg E, Castelein S, Stewart R, et al, for the Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res. 2013;47(6):718-725. doi:10.1016/j.jpsychires.2013.01.024 PubMed
29. Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2007;165(1):82-89. doi:10.176/api.ajp.207.07050724 PubMed
30. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040-1047. doi:10.176/api.ajp.208.0707135 PubMed
31. Umbricht D, Lentz E, Santarelli L, et al. A post-hoc analysis of the negative symptom factor score in a proof-of-concept study of glycine reuptake inhibitor bitopertin in schizophrenia. Papers of the 25th ECNP Congress. October 13-17, 2012; Vienna, Austria. Eur Neuropsychopharmacol. 2012;22(suppl 2):SB11.